Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase 2 1

Status

Terminated 10Completed 8Withdrawn 6Unknown 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1Genitourinary 1CNS 1

Conditions

Cholangiocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Acrocephalosyndactylia 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × infigratinib × Clear all
NCT05514912 2023-12-26

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Emory University

Phase 2 Withdrawn
Gastrointestinal

Cholangiocarcinoma

NCT05510427 2023-08-15

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Gastrointestinal

Liver Neoplasms, Cholangiocarcinoma

NCT05222165 2023-02-23

NEWEL

Helsinn Healthcare SA

Phase 1/2 Withdrawn
CNS

Central Nervous System Neoplasms

NCT04972253 2022-08-10

(BLASST)-3

Dana-Farber Cancer Institute

Phase 1 Withdrawn
Genitourinary

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT02575508 2016-05-20

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Roswell Park Cancer Institute

Phase 1/2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms

NCT02312804 2015-02-16

Ph Ib/BGJ398/Cervix and Other Solid Tumors

The University of Texas Health Science Center at San Antonio

Phase 1 Withdrawn
Gynecologic

Uterine Cervical Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡